pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Entresto
drug
save

Entresto

Marketedupdated 3mo ago
by $NVS NOVARTIS AG
Approved
community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying Entresto

  • phase1Bioequivalence Study of Valsatril Tablet Versus Entresto® (Sacubitril/Valsartan 24/26mg) 24mg/26mg Tablet.completedn=60
  • —Special Drug Use Surveillance of Entresto Tablets (Hypertension)completedn=1,125
  • phase2Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019completedn=42
  • phase1A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditionsunknownn=48
  • phase1A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditionsunknownn=48
  • phase1A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditionsunknownn=48

News(4)

  • STAT+: PBMs agree to display TrumpRx drug prices
    Bristol's Zenbexus wins accelerated approval, Novartis wins UK patent fight over Entresto, and more biotech news from The Readout
    stat · 2h ago
  • Novartis climbs on upbeat drug sales as key readouts loom
    A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.
    biopharma_dive · 24d ago
  • Novartis stays 'geography-agnostic' in dealmaking amid flurry of China deals
    Novartis will continue to be on the lookout for bolt-on deals below $2 billion, CEO Vas Narasimhan said Tuesday on the pharma's second quarter earnings call—though major pickups aren’t completely o…
    biospace · 24d ago
  • STAT+: Boehringer’s obesity drug shows 16.6% weight loss; more data needed
    Eli Lilly's deal with Profluent, Erasca's RAS-targeting cancer pill, and more biotech news today
    stat · 3mo ago
brand
Entresto
generic
(sacubitril + valsartan)
indication
Cardiovascular Risk Factors
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 47m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?